High placebo responses common in tests of neuropsychiatric drugs make any clinical trial in major depressive disorder risky. Intra-Cellular Therapies now has data showing its drug met key goals of a ...
When prescription depression drugs fall short in efficacy, there’s an off-label way to help them work better: add-on doses of thyroid hormone. Clinicians have long known about this approach and some ...
Depression is one of the most widespread mental health disorders worldwide, affecting approximately 4% of the global ...
Biotech stock GH Research catapulted Monday after the FDA gave it the go-ahead to resume testing its depression drug.
Supernus Pharmaceuticals has linked its mTORC1 activator to rapid improvements in adults with major depressive disorder (MDD) in a small trial, pointing to one possible path forward for a candidate ...
Jan 2 (Reuters) - Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and ...
Psychedelic drugs—often associated with 1960s counterculture—are attracting newfound attention from physicians and neuroscientists who are studying their potential to help people suffering from an ...
Anti-inflammatory medications reduce depressive symptom severity and anhedonia in individuals with depression and elevated levels of inflammation, according to a new study published in the American ...
What if there were tests that could tell you whether the following drugs were a good match for your patients: Antidepressants, statins, painkillers, anticlotting medicines, chemotherapy agents, HIV ...
ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. These highlights were written by the reporters and editors ...
Actinogen Medical’s hopes—and stock price—have rebounded slightly from earlier this month, when the Australian biotech announced its cortisol blocker had failed to improve attention and memory in ...